Browse Articles | Gene Therapy

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-02T23:55:36.655Z • Permanent link

Regulatory scrutiny is intensifying on the gene therapy sector, with the FDA approving a new therapy for a rare genetic disorder, raising questions about the industry's long-term prospects. Novartis, a Swiss multinational pharmaceutical company, has submitted an application for its gene therapy, Zolgensma, to treat spinal muscular atrophy in children. Zolgensma has already been approved in the US, Canada, and several European countries, with prices ranging from $2.1 million to $4.2 million, depending on the country.

Novartis has partnered with a non-profit organization, the Children's Tumor Foundation, to make the therapy available to patients in need. The company's strategy is to focus on rare genetic disorders, where the need for effective treatments is high. Zolgensma has shown significant promise in clinical trials, with patients experiencing significant improvements in motor function and quality of life. The therapy works by replacing a faulty gene with a healthy one, allowing the body to produce a functional protein.

Critics have raised concerns about the high cost of the therapy, which has led to increased prices for similar treatments. The FDA has stated that it will continue to review the safety and efficacy of gene therapies, including Zolgensma, to ensure that they meet high standards. Novartis has defended its pricing strategy, citing the high costs of research and development for the therapy.

The approval of Zolgensma has significant implications for the gene therapy industry, with companies such as CRISPR Therapeutics and Editas Medicine working on similar therapies for a range of genetic disorders. The FDA's approval of Zolgensma has set a precedent for the industry, with companies looking to follow suit. However, the high cost of the therapy has raised concerns about accessibility, particularly in countries with limited resources.

The approval of Zolgensma has also sparked debate about the role of gene editing in the treatment of genetic disorders. Some experts have raised concerns about the ethics of gene editing, particularly in the context of rare genetic disorders. Others have argued that gene editing has the potential to revolutionize the treatment of genetic disorders, providing new hope for patients and families. The FDA's approval of Zolgensma has highlighted the need for ongoing debate and discussion about the role of gene editing in medicine.

The approval of Zolgensma is part of a larger trend in the gene therapy sector, with companies working on a range of therapies for rare genetic disorders. The sector has seen significant investment in recent years, with companies such as CRISPR Therapeutics and Editas Medicine securing funding from venture capitalists and pharmaceutical companies. The FDA has also taken a more active role in reviewing gene therapies, with a new framework for evaluating the safety and efficacy of these therapies.